Nkarta, Inc. stock is up 18.48% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 December’s closed higher than November. In the last 6 Unusual Options Trades, there were 3 CALLs, 3 PUTs. 100% of analysts rate it a buy.
|Date & Time||Expiration Date||Strike Price||Trade Type||Size||Open Interest|
|17 Oct 16:02||17 Nov, 2023||2.50||2117|
|17 Oct 16:15||17 Nov, 2023||2.50||2117|
|17 Oct 16:21||16 Feb, 2024||2.50||619|
|17 Oct 16:52||17 Nov, 2023||5.00||0|
|20 Oct 19:38||17 Nov, 2023||5.00||562|
|03 Nov 19:23||15 Dec, 2023||2.50||150|
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens.